Notably, parental melanoma cells sensitive to BRAF inhibitors were not affected by Gal-1-targeting siRNAs or a peptidomimetic inhibitor, which is consistent with the fact that the receptor NRP1 is almost undetectable and that the autocrine signaling circuit described here is not active in these cells. This evidence concerns the gene BRAF and melanoma.